Eurazeo, an investment company, completed the acquisition of a minority stake in Horus Pharma, a pharmaceuticals company specialising in ophthalmology, for $25m. “Nov Santé’s dedicated team is very happy to be working with the Claret family on the next phase of their company’s expansion. For the first time since the fund was launched, we are investing via a near-equity instrument. This is fully in line with the business plan being developed by Horus Pharma, which will benefit from all of Eurazeo’s expertise in healthcare and private equity," Arnaud Vincent, Eurazeo Managing Director.